Group 1 - The three major US stock indices closed higher, reaching new historical highs, with the Nasdaq up 1.15%, the Dow Jones up 1.01%, and the S&P 500 up 0.79% [1] - Large-cap tech stocks mostly rose, with Nvidia and Google increasing over 2%, while Amazon and Apple rose over 1% [1] - Tesla fell over 3% and Netflix dropped over 1%, while Ford Motor Company surged over 12%, marking its best single-day performance since March 2020 [1] Group 2 - The Nasdaq China Golden Dragon Index rose 0.27%, with notable gains in Chinese concept stocks such as Arctech Solar up 6.01% and WeRide up 5.14% [1] - Other Chinese stocks like Century Internet, Trip.com, and JinkoSolar saw increases of up to 2.45%, while companies like Li Auto and Yum China experienced declines of 1.39% and 1.58% respectively [1] - Micron Technology rose nearly 6%, reaching a historical high, while Unusual Machines increased over 8% [1]

Core Points - The Hong Kong Innovative Drug ETF (159567) closed down 0.12% with a trading volume of 797 million yuan on October 24, 2024 [1] - The fund was established on January 3, 2024, with a management fee of 0.50% and a custody fee of 0.10% [1] - As of October 23, 2024, the fund's latest share count was 8.225 billion shares, with a total size of 6.801 billion yuan, reflecting a year-to-date increase of 1980.29% in shares and 1700.12% in size [1] Fund Performance - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 65.38% during the tenure [2] - The fund's performance benchmark is the National Index for Hong Kong Innovative Drugs, adjusted for valuation exchange rates [1] Liquidity and Trading Activity - Over the last 20 trading days, the ETF has accumulated a trading amount of 22.849 billion yuan, with an average daily trading amount of 1.142 billion yuan [1] - Since the beginning of the year, the ETF has recorded a total trading amount of 227.996 billion yuan over 195 trading days, averaging 1.169 billion yuan per day [1] Top Holdings - The ETF's top holdings include: - Innovent Biologics (9.52% holding, 26 million yuan market value) - WuXi Biologics (9.47% holding, 25.8 million yuan market value) - BeiGene (8.73% holding, 23.8 million yuan market value) - CanSino Biologics (7.62% holding, 20.8 million yuan market value) - China National Pharmaceutical Group (7.17% holding, 19.6 million yuan market value) [2]

Market Performance - The three major U.S. stock indices all closed higher, with the Dow Jones up 0.31%, S&P 500 up 0.58%, and Nasdaq up 0.89% [4] - Major technology stocks also saw gains, with the Nasdaq China Golden Dragon Index rising 1.66% and the Wind China Technology Leaders Index increasing by 2.65% [11] - Notable individual stock performances included Tesla up 2.28%, Amazon up 1.44%, and Nvidia up 1.04% [8][9] Chinese Stocks - Chinese stocks outperformed the broader market, with Meituan rising 5.01%, Alibaba up 3.65%, and Baidu up 2.95% [13][14] - The performance of other Chinese companies included Pinduoduo up 2.48%, Tencent Holdings up 2.34%, and JD.com up 2.22% [14] Oil Prices - International oil prices surged due to geopolitical tensions, with U.S. crude oil rising 5.56% to $61.75 per barrel and Brent crude oil increasing by 5.38% to $65.96 per barrel [15][17] - The U.S. Treasury announced sanctions against Russian oil companies, contributing to concerns over potential disruptions in Russian oil supply, which further drove up oil prices [17] - UBS forecasts that Brent crude prices will remain in the $60 to $70 per barrel range, while Citigroup suggests that prices could drop to $50 to $55 per barrel if negotiations between Russia and Ukraine progress quickly [17] Geopolitical Developments - The White House indicated that a meeting between President Trump and President Putin is not entirely off the table, despite recent tensions [19] - President Putin commented that the new U.S. sanctions are unfriendly but will not significantly impact the Russian economy, emphasizing the importance of dialogue over confrontation [21][22]

Market Overview - The US stock indices all closed higher, with the Dow Jones up 0.31%, S&P 500 up 0.58%, and Nasdaq up 0.89% [4][5] - Major tech stocks also saw gains, with the Tech Giants Index rising 0.70% [9] Individual Stock Performance - Notable performers included Honeywell International, which rose 6.81%, and 3M Company, which increased by 2.61% [5] - Tesla increased by 2.28%, Amazon by 1.44%, and Nvidia by 1.04%, leading the tech sector [10][11] Chinese Stocks Performance - Chinese stocks outperformed the broader market, with the Nasdaq Golden Dragon China Index up 1.66% and the Wind China Technology Leaders Index up 2.65% [12][13] - Meituan rose 5.01%, Alibaba increased by 3.65%, and Baidu gained 2.95%, leading the Wind China Technology Leaders Index [15][16] Oil Price Surge - International oil prices surged due to geopolitical tensions, with US oil closing up 5.56% at $61.75 per barrel, and Brent crude rising 5.38% to $65.96 per barrel [18][20] - The surge was driven by fears of potential disruptions in Russian oil supply following new sanctions from the US and EU [20][21] Geopolitical Developments - The White House indicated that a meeting between President Trump and President Putin is not entirely out of the question, despite recent tensions [22][23] - Putin commented that the new US sanctions are unfriendly but will not significantly impact the Russian economy, emphasizing the importance of dialogue over confrontation [25]

Market Performance - The three major U.S. stock indices all closed higher, with the Dow Jones Industrial Average rising by 0.31%, the S&P 500 increasing by 0.58%, and the Nasdaq Composite gaining 0.89% [2][3] - Major technology stocks also saw gains, with the Nasdaq China Golden Dragon Index up by 1.66% and the Wind China Technology Leaders Index rising by 2.65% [16] Individual Stock Movements - Honeywell International surged by 6.81%, 3M Company increased by 2.61%, and Amazon rose by 1.44%, leading the Dow [3] - Among Chinese concept stocks, Meituan rose by 5.01%, Alibaba increased by 3.65%, and Baidu gained 2.95%, leading the Wind China Technology Leaders Index [19][20] Oil Price Surge - International oil prices surged due to geopolitical tensions, with U.S. crude oil futures rising by 5.56% to $61.75 per barrel, and Brent crude oil futures increasing by 5.38% to $65.96 per barrel [21] - The U.S. Treasury announced sanctions against Russian oil companies, contributing to concerns over potential disruptions in Russian oil supply, which further drove up oil prices [21] Geopolitical Developments - The White House indicated that a meeting between President Trump and President Putin is not entirely out of the question, despite recent tensions [22] - President Putin stated that the recent U.S. sanctions are unfriendly and will not significantly impact the Russian economy, emphasizing the importance of dialogue over confrontation [25]

Core Viewpoint - CATL (Contemporary Amperex Technology Co., Limited) has demonstrated significant financial growth in Q3 2025, achieving record profits and revenue, while also expanding its market presence internationally and diversifying its business model towards energy storage and consumer markets [4][6][14]. Financial Performance - In Q3 2025, CATL reported revenue of 1041.86 billion yuan, a year-on-year increase of 12.90%, and a net profit of 185.49 billion yuan, up 41.21%, marking the highest quarterly profit in the company's history [4][11]. - For the first three quarters of 2025, total revenue reached 2830.72 billion yuan, with a year-on-year growth of 9.28%, and net profit increased by 36.20% to 490.34 billion yuan [5][6]. - The company's operating cash flow for the first three quarters was 806.6 billion yuan, reflecting a 19.6% increase, indicating strong self-financing capabilities [7][11]. Profitability and Margins - CATL's net profit margin in Q3 reached 19.1%, an increase of 4.1 percentage points compared to the same period last year, highlighting improved profitability [15]. - The company achieved an average daily profit of over 200 million yuan in Q3, compared to less than 140 million yuan in the previous year [13]. Market Position and Challenges - Despite maintaining a leading position in the global electric vehicle battery market with a 36.8% share, CATL's market share has slightly declined from 37.7% year-on-year [24]. - In the domestic market, CATL's share decreased by 3.1 percentage points to 42.75%, marking the lowest level in five years [24]. International Expansion and Strategy - CATL's overseas revenue reached 612 billion yuan in the first half of 2025, accounting for 34.22% of total revenue, with plans to increase overseas production capacity to 40% by 2026 [27]. - The company is focusing on expanding its presence in Europe and North America, with significant market shares of 35% and 28% respectively [28]. - The funds raised from the Hong Kong IPO are primarily allocated for overseas capacity construction, particularly in Hungary [27][29]. Diversification into Energy Storage - CATL is increasing its focus on energy storage systems, which accounted for approximately 20% of its total shipments in Q3 2025 [31]. - The company is expanding its production capacity for energy storage batteries across multiple locations in China, anticipating significant demand from data centers [31]. New Business Ventures - CATL is entering the consumer market with its battery swapping service, targeting the C-end market for the first time, which could open new growth avenues [33][34].

Core Viewpoint - The company, Zai Lab (09688.HK), announced that its board's audit committee will review and approve the unaudited quarterly performance for the third quarter ending September 30, 2025, on November 6, 2025, in accordance with US GAAP and SEC regulations [1] Group 1 - The board's audit committee is scheduled to meet on November 6, 2025 [1] - The meeting will focus on the unaudited quarterly results for the three and nine months ending September 30, 2025 [1] - The results will be prepared in compliance with US GAAP and applicable SEC rules [1]

Zai Lab Limited 再鼎醫藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：9688） 審核委員會行動通告及 2025 年第三季度業績公告的發佈日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 在第三季度業績獲批准及發佈後，本公司管理層計劃在 2025 年 11 月 6 日（星期四，美國東部時間） 上午 8:00/2025 年 11 月 6 日（星期四，香港時間）下午 9:00 舉行現場業績電話會議及網絡直播，以討 論第三季度業績並回答提問。有意參會人士可透過本公司網站 http://ir.zailaboratory.com 參與網絡直播。 所有參與者均須於電話會議前透過下文提供的連結完成線上登記流程。登記後，參與者將收到提供撥 號詳情的確認郵件。 網絡直播登記連結： https://edge.media-server.com/mmc/p/svanah67 拨入登記連結：https://register-conf.med ...

- 1 - (A) 人數。委員會應由至少三名成員組成。 (B) 獨立性。委員會的每名成員均應符合納斯達克全球市場（「納斯達克」）及香 港聯合交易所有限公司證券上市規則（「香港上市規則」）的適用獨立性 要求，並符合「獨立董事」的資格。 (C) 主席。除非主席由董事會委任，否則委員會成員應通過委員會全體成員的 多數票指定一名主席。主席應領導委員會，包括制定會議議程、主持會議、 分配小組委員會任務及代表委員會向董事會報告。 (D) 關於成員資格的決定。委員會的成員應由董事會委任並可由董事會酌情罷 免。董事會將至少每年評估是否符合上述成員資格要求。 再鼎醫藥有限公司董事會 提名及企業管治委員會章程 （於2025年10月22日獲董事會採納） I. 宗旨和權限。 再鼎醫藥有限公司（「公司」）董事會（「董事會」）下設的提名及企業管治委員會（「委 員會」）的宗旨是履行董事會授予有關企業管治及董事提名的職責。 II. 組成。 III. 程序和管理。 (A) 董事會和委員會事務；企業管治。 (1) 董事提名人選。委員會應按董事會批准的標準物色有資格成為董事會成 員的人士，接收並審查有關合格人士的提名及審查首席執行官提出的推 薦； ...

Market Performance - The Hang Seng Healthcare Index decreased by 2.71% as of October 23, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 2.41%, with a latest price of 0.65 CNY, but has seen a 3.42% increase over the past three months [2] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.70%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 3.26% [4][5] - The CSI Pharmaceutical 50 Index declined by 0.95%, while the Pharmaceutical 50 ETF (159838) decreased by 0.96% [6] Liquidity and Trading Activity - The Hang Seng Medical ETF had a turnover of 11.25% and a trading volume of 763 million CNY, indicating active market participation [2] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.44% with a trading volume of approximately 98.5 million CNY [5] - The Pharmaceutical 50 ETF had a turnover of 1.67% and a trading volume of 2.71 million CNY [6] Key Events and Trends - The flu season has started early, leading to a rise in flu-related stocks, with companies like Hendi Pharmaceutical and Duori Pharmaceutical seeing significant gains [7] - The ongoing ESMO (European Society for Medical Oncology) conference has heightened interest in Chinese pharmaceutical companies, showcasing clinical data from firms like Heng Rui Pharmaceutical and Ke Long Bo Tai [7] - The collaboration between Sinopharm and Takeda is expected to enhance foreign investment confidence in Chinese innovative drug assets [7] Industry Insights - The Chinese innovative drug sector is accelerating its international presence, with 135 licensing-out transactions recorded from January to October 17, 2025, totaling over 102.9 billion USD [7] - The ESMO conference highlighted 23 LBA studies led by Chinese scholars, demonstrating the global competitiveness of China's innovative drug pipeline [7] - The aging population is increasing the demand for chronic disease treatments, while the optimization of the medical insurance payment system and AI technology applications are injecting new vitality into the industry [8] ETF Overview - The Hang Seng Medical ETF has a current scale of 6.865 billion CNY, ranking in the top third among comparable funds [8] - The Hong Kong Innovative Drug Selection ETF reached a new high with a scale of 468 million CNY [10] - The Pharmaceutical 50 ETF tracks the top 50 pharmaceutical companies in China, with the top ten stocks accounting for 59.46% of the index [11]